



Easy to learn, easy to employ

Rule out more unnecessary biopsies


An easy way to add a revenue-driving service

Provides an instant Investigate Further or Monitor result

Enables early detection using non-invasive optical spectroscopy

Supporting Data

Of all the lesions biopsied by dermatologists, DermaSensor correctly reported 92% of cancers and 95% of melanomas as needing further investigation while ruling out 32% of benign lesions as ones to monitor.^{2,4}



Schedule a live demo to learn more about **DermaSensor** today.

📞 1300 LESION (1300 537 466)


💻 www.dermasensor.com



DermaSensor

THE ONLY SKIN CANCER
DETECTION TOOL DESIGNED
SPECIFICALLY FOR GP'S

Assess, Analyze, Act





Assess

After you've performed a full-body examination of the patient to identify lesions of concern, you can use the DermaSensor device to capture data on those lesions.

Analyze

The DermaSensor device will help you provide a fast and accurate analysis of the lesions of concern, returning either an Investigate Further or Monitor result for each lesion.



Act

Depending on results, you'll counsel your patient on next steps, either continuing to confirm malignancy by biopsy, or reliably ruling out an unnecessary excision with a Monitor result.¹⁻⁴

The DermaSensor device is currently CE Marked and is registered and available for sale in Australia and New Zealand. To learn more about the benefits and risks of the device and how to purchase, please visit www.dermasensor.com.

Spectral Scoring



¹Salmon P and Bonning M. Use of Elastic-scattering Spectroscopy and Machine Learning When Assessing Skin Lesions Suggestive of Skin Cancer, Poster Presentation, SDPA Fall Conference, Nov 4-7, 2021

²Benvenuto-Andrade C, Manolagos D and Cognetta AB. Safety and Effectiveness of Elastic Scattering Spectroscopy and Machine Learning in the Evaluation of Skin Lesions for Cancer, Poster Presentation, 8th World Congress of Teledermatology, Imaging and AI for Skin Disease, Nov 5-6, 2020.

³Tepedino K, Tablada A, Barnes E, Da Silva T. Clinical Utility of a Handheld Elastic Scattering Spectroscopy Tool and Machine Learning on the Diagnosis and Management of Skin Cancer by Primary Care Physicians, Poster Presentation, SDPA Fall Conference, Nov 4-7, 2021.

⁴Data on file.

The DermaSensor Process



Rapid Recording

Evaluation process provides a result to support your clinical decision at the point of care



Easy to Use

Wireless, ergonomic design makes the device intuitive to learn and easy to use



Optical Spectroscopy

Light-emitting tip non-invasively touches the lesion, receiving and analyzing data from below the skin



Risk Assessment

Provides an instant, objective result using DermaSensor's proprietary algorithm



Interpreting Result

For lesions found to contain properties associated with malignant lesions, the device will display Investigate Further and a score between 1-10 to indicate the degree of similarity to malignant lesions in studies